

# The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome

William C. Aird

Severe sepsis, defined as sepsis with acute organ dysfunction, is associated with high morbidity and mortality rates. The development of novel therapies for sepsis is critically dependent on an understanding of the basic mechanisms of the disease. The pathophysiology of severe sepsis involves a highly complex, inte-

grated response that includes the activation of a number of cell types, inflammatory mediators, and the hemostatic system. Central to this process is an alteration of endothelial cell function. The goals of this article are to (1) provide an overview of sepsis and its complications, (2) discuss the role of the endothelium in

orchestrating the host response in sepsis, and (3) emphasize the potential value of the endothelium as a target for sepsis therapy. (Blood. 2003;101:3765-3777)

© 2003 by The American Society of Hematology

## Introduction

Sepsis is the most common cause of death among hospitalized patients in noncoronary intensive care units. Thus, an important goal in critical care medicine is to develop novel therapeutic strategies that will impact favorably on patient outcome. Unfortunately, the pathophysiology of severe sepsis remains poorly defined. While it is generally accepted that sepsis-associated mortality is related to the host response and involves a multitude of cell types, inflammatory mediators, and coagulation factors, clinical studies have largely failed to identify an effective therapeutic target. Future advances in sepsis therapy will require a better understanding of how the individual components of the host response interact. The endothelium plays a critical role in mediating the sepsis phenotype. This article provides an overview of sepsis and its complications, discusses the role of the endothelium in orchestrating the host response in sepsis, and emphasizes the potential value of the endothelium as a target for sepsis therapy.

cells). Severe sepsis is sepsis complicated by organ dysfunction. Septic shock (hypotension despite adequate fluid resuscitation) is a subcategory of severe sepsis. At the end of the spectrum is multiple organ dysfunction syndrome (MODS), defined as the presence of altered organ function in an acutely ill patient such that homeostasis cannot be maintained without intervention.

## Epidemiology

In 1990, the Centers for Disease Control and Prevention reported an estimate of 450 000 cases of septicemia per year in the United States, with over 100 000 deaths.<sup>3</sup> Recently, Angus et al estimated that 750 000 cases of severe sepsis occur per year, with a mortality rate of 28.6%.<sup>4</sup> Other studies suggest that 28-day mortality rates of severe sepsis may be 50% or greater.<sup>5</sup> According to Angus et al, the mortality rate due to severe sepsis represented 9.3% of all deaths in the United States in 1995.<sup>4</sup> The average cost per case was \$22 100, with annual costs of \$16.7 billion nationally. Importantly, the incidence of severe sepsis was projected to increase by 1.5% per year.<sup>4</sup> Taken together, these data suggest that severe sepsis is a serious public health concern.

## Clinical manifestations

The most common clinical findings in sepsis are related to SIRS (eg, fever, tachycardia, tachypnea, and leukocytosis) and organ dysfunction (eg, acute lung injury, acute respiratory distress syndrome, shock). Laboratory markers of inflammation include high circulating levels of interleukin 6 (IL-6), IL-8, and tumor necrosis factor alpha (TNF- $\alpha$ ).<sup>6-8</sup> Activation of the coagulation cascade is most often manifested by increased D-dimer levels ( $\approx$  100% patients) and decreased levels of circulating protein C ( $\geq$  90% patients).<sup>9-11</sup> In contrast, less than half of patients with sepsis meet the definition of disseminated intravascular coagulation (DIC),<sup>1,12,13</sup> a syndrome that is characterized by widespread

## Overview of the sepsis continuum

### Definition

Sepsis and its sequelae represent a continuum in clinical-pathologic severity. However, it is one with definable phases that characterize patients at risk for increased mortality.<sup>1</sup> The American College of Chest Physicians and the Society of Critical Care Medicine established a set of definitions to facilitate early detection and treatment of sepsis and to standardize patient requirements for research protocols.<sup>2</sup> Infection is defined as an inflammatory response to microorganisms or the invasion of normally sterile host tissue by those organisms. Sepsis represents the systemic inflammatory response to infection and is manifested by 2 or more of the systemic inflammatory response syndrome (SIRS) criteria (eg, changes in body temperature, tachycardia, tachypnea and/or hypocapnia, and changes in the number and/or immaturity of white blood

From the Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

Submitted July 9, 2002; accepted January 7, 2003. Prepublished online as *Blood* First Edition Paper, January 23, 2003; DOI 10.1182/blood-2002-06-1887.

Supported in part by National Institutes of Health grants HL 60585-03, HL

63609-02, and HL 65216-02.

Reprints: William C. Aird, Molecular Medicine, Beth Israel Deaconess Medical Center, RW-663, 330 Brookline Ave, Boston, MA 02215; e-mail: waird@caregroup.harvard.edu.

© 2003 by The American Society of Hematology

activation of coagulation, fibrin deposition, and thrombotic occlusions and/or bleeding.<sup>14,15</sup>

### Pathophysiology


There are several important themes in sepsis pathophysiology. First, it is the host response, rather than the nature of the pathogen, that primarily determines patient outcome. Second, monocytes and endothelial cells play a central role in initiating and perpetuating the host response. Third, sepsis is associated with the concomitant activation of the inflammatory and coagulation cascades. Finally, in a concerted effort to fend off and eliminate pathogens, the host response may inflict collateral damage on normal tissues, resulting in pathology that is not diffuse, but rather remarkably focal in its distribution. Each of these themes will be discussed in turn.

**The importance of the host response.** Several findings point to the importance of host factors in determining outcomes in patients with severe sepsis. First, despite the prompt implementation of appropriate antibiotic therapy, sepsis mortality remains high, in the range of 28% to 50%. Second, patients with culture-positive and culture-negative sepsis or septic shock have comparable mortality rates.<sup>1,5</sup> Third, administration of anti-endotoxin antibodies in large, clinical trials did not improve survival.<sup>16,17</sup> Last, there is a direct correlation between the number of SIRS criteria and mortality rate, and there is a stepwise increase in mortality rates in the spectrum of SIRS, sepsis, severe sepsis, and septic shock.<sup>1</sup> Clearly, the success of future therapies will rely on the ability to adequately target the host response.

**Role of the monocyte and endothelial cell in mediating the host response.** Monocytes, tissue macrophages, other myeloid-derived cells, and to some extent endothelial cells, are the cornerstones of the innate immune response. As a first line of defense, these cells recognize invading pathogens through pattern recognition receptors that interact with conserved microbial structures.<sup>18-25</sup> The interaction between pathogens and host cells results in the initiation of inflammatory and coagulation cascades (Figure 1). These pathways yield soluble mediators that function in autocrine or paracrine loops to further activate the monocyte/tissue macrophage and/or endothelium.

**Activation of the inflammatory and coagulation pathways.** It is widely accepted that the inflammatory response plays an important role in mediating the sepsis phenotype. Pathogens promote the early activation of the contact system (factor XII, prekallikrein, and high-molecular-weight kininogen) and the complement cascade, and induce the rapid release of inflammatory mediators from a number of cell types (eg, monocytes and endothelial cells), changes that correspond to the clinical designation of SIRS. Simultaneously, endogenous antiinflammatory pathways are activated, which serve to dampen the inflammatory response.<sup>26-30</sup> The latter process has been termed the compensatory anti-inflammatory response syndrome.<sup>27</sup> Ideally, these 2 phases are coordinated to defend the host against invasion by pathogens. However, an excessive or sustained inflammatory response, an inadequate anti-inflammatory response, or perhaps an uncoupling of these 2 phases may contribute to tissue damage and death.

Besides activating the inflammatory system, pathogens also trigger the clotting cascade.<sup>31</sup> During sepsis, tissue factor (TF) expression on the surface of circulating monocytes and tissue macrophages is up-regulated, resulting in activation of the extrinsic pathway, thrombin generation, and fibrin formation. Fibrin not only stabilizes platelet plugs, but may also play an important role in immobilizing pathogens on the surface of the leukocyte, facilitating their engulfment and disposal. Blood coagulation is initiated through the extrinsic pathway and is amplified through the intrinsic



**Figure 1. The role of the monocyte and endothelium in mediating the host response to infection.** LPS and/or other pathogen-associated properties activate pathogen recognition receptors (or toll-like receptors) on monocytes, tissue macrophages, and endothelial cells, leading to the release of inflammatory mediators and tissue factor (with subsequent activation of coagulation). Together with products of the contact system (eg, kinins) and complement cascade (eg, C5a) (not shown), inflammatory mediators function in autocrine and paracrine loops to further activate the monocyte and local endothelium (dotted line, left, shows paracrine pathway). The various components of the coagulation cascade serve not only to activate their downstream substrate (leading to fibrin formation) but also to trigger protease-activated receptors on the surface of a variety of cell types, including the endothelium (broken line, right). The combined effects of LPS, inflammatory mediators, and serine proteases on the endothelium may result in significant phenotypic modulation (not shown). CAM indicates cell adhesion molecules; PAF, platelet activating factor; NO, nitric oxide; ROS, reactive oxygen species; MIP-2, macrophage inflammatory protein 2.

pathway by mechanisms that involve cross-talk and feedback.<sup>31-35</sup> The clotting cascade is composed of a series of linked reactions in which a serine protease, once activated, is free to activate its downstream substrate. These reactions occur on activated phospholipid membranes and in some cases are accelerated by the presence of cofactors (factors VIIIa and Va). For every procoagulant response there is a natural anticoagulant reaction. Tissue factor pathway inhibitor (TFPI) controls the extrinsic pathway,<sup>36</sup> antithrombin III (ATIII)-heparan neutralizes the serine proteases in the cascade,<sup>37</sup> the thrombomodulin (TM)/protein C/protein S mechanism inactivates cofactors Va and VIIIa,<sup>38</sup> and plasmin degrades preformed fibrin. Hemostasis represents a finely tuned balance between procoagulant and anticoagulant forces. Not only is there activation of the extrinsic pathway in sepsis, but there is also an attenuation of natural anticoagulant responses (eg, reduction in circulating levels of protein C and ATIII, decreased expression of TM on the surface of endothelial cells, impaired fibrinolysis).<sup>31,39-42</sup> The resulting shift toward a procoagulant state results in excessive thrombin generation, fibrin formation, and consumption of clotting factors.

Once activated, the inflammatory and coagulation pathways interact with one another to further amplify the host response (Figure 1). For example, inflammatory mediators induce the expression of TF on the surface of circulating monocytes, tissue macrophages, neutrophils, and possibly some subsets of endothelial cells.<sup>43-49</sup> Conversely, serine proteases are capable of interacting with protease-activated receptors on the surfaces of monocytes and endothelial cells, leading to activation and additional inflammation.<sup>50,51</sup> For

example, thrombin signaling in endothelial cells results in changes in cell shape,<sup>52</sup> cell permeability,<sup>53</sup> proliferative response,<sup>54</sup> and leukocyte adhesion.<sup>55-58</sup> The latter changes are mediated in large part by the ability of thrombin to induce the expression of E-selectin,<sup>59</sup> P-selectin,<sup>55,57</sup> intercellular adhesion molecule 1 (ICAM-1),<sup>56,58</sup> and vascular cell adhesion molecule 1 (VCAM-1).<sup>58,60</sup> In addition, thrombin signaling in endothelial cells has been shown to induce the secretion of von Willebrand factor (VWF),<sup>61</sup> increase the expression of protease-activated receptor 1 (PAR-1) mRNA,<sup>62</sup> and stimulate the release of soluble mediators, including platelet-activating factor (PAF),<sup>63</sup> IL-8,<sup>59,64</sup> monocyte chemoattractant protein 1 (MCP-1),<sup>65</sup> growth factors, and matrix metalloproteinases.<sup>66</sup> TF/VIIa complex and factor Xa may also bind to protease-activated receptors and trigger a proinflammatory response.<sup>67-70</sup> Finally, fibrin(ogen) has been shown to interact with endothelial cells, leading to a number of phenotypic changes including increased expression of IL-8.<sup>71,72</sup> The cross-talk between inflammatory and coagulation pathways contributes to the potentially explosive host response to sepsis.

**Focal expression of sepsis phenotype.** A consistent feature of the pathologic lesions in severe sepsis and MODS is the focal nature of their distribution. Typically, patients only develop dysfunction in a limited number of organs. The endothelium is an important determinant of the focal response in sepsis. As discussed below, the endothelium displays remarkable heterogeneity in health and disease states, integrating systemic changes in inflammation and coagulation in ways that differ from one organ to the next.

## Role of the endothelium in orchestrating the host response in sepsis

### Endothelial cell activation and dysfunction

The endothelium is a truly pervasive organ; the human body contains approximately  $10^{13}$  endothelial cells, weighing 1 kg and covering a surface area of 4000 m<sup>2</sup> to 7000 m<sup>2</sup>.<sup>73</sup> Among other functions, the endothelium mediates vasomotor tone, regulates cellular and nutrient trafficking, maintains blood fluidity, contributes to the local balance in proinflammatory and anti-inflammatory mediators, participates in generation of new blood vessels, and undergoes programmed cell death.<sup>74-76</sup> Importantly, each of these activities is differentially regulated in space and time (a phenomenon that has been variably termed endothelial cell heterogeneity or vascular diversity).<sup>31,75,77-79</sup>

Under normal conditions, endothelial cells are highly active, constantly sensing and responding to alterations in the local extracellular environment, as might occur in the setting of transient bacteremia, minor trauma, and other common daily stresses. In other words, endothelial cell activation occurs as a normal adaptive response, the nature and duration of which depends not only on the type of stimulus, but also on the spatial and temporal dynamics of the system.<sup>80</sup> For example, at any given time, the endothelial cells of a vein and artery may have distinct response patterns to a common systemic signal, while at any given site, the response will vary from one moment to the next, according to health and state of the whole organism. Therefore, endothelial cell activation is not an all-or-nothing response, nor is it necessarily linked to disease. Instead, endothelial cell activation represents a spectrum of response and occurs under both physiologic and pathophysiologic conditions.

Any response of the endothelium that benefits the host may be deemed functional, physiologic, or adaptive. For example, when pathogens invade a tissue, endothelial cells are induced locally to release inflammatory mediators, to recruit leukocytes, and to

promote clotting as a means of walling off the infection. During this process, endothelial cells may undergo necrosis or apoptosis as tissue is reabsorbed and repaired. When viewed at the level of the single cell, necrosis and/or apoptosis are the ultimate expression of dysfunction. However, when considered in the larger context of host defense, the local loss of endothelium is part of a larger coordinated, adaptive response. Perhaps a fitting analogy is group altruism or group selection, an evolutionary mechanism of cooperation in animals, in which group-level positive effects outweigh the individual-level negative effects. The term endothelial cell dysfunction is better reserved for cases in which the endothelial cell response, whether local or systemic, represents a net liability to the host. For example, in severe sepsis, there is an excessive, sustained, and generalized activation of the endothelium. Without artificial organ support, virtually all patients with severe sepsis would die from their disease. In other words, most of these individuals have crossed the threshold from an adaptive to a maladaptive response. In so far as the endothelium contributes to the severe sepsis phenotype, its behavior may be characterized as dysfunctional.

### Endothelial response in severe sepsis

Sepsis may induce phenotypic modulation of the endothelium by a number of different mechanisms. In some cases, pathogens directly infect intact endothelial cells.<sup>81</sup> More commonly, components of the bacterial wall (eg, lipopolysaccharide [LPS]) activate pattern recognition receptors on the surface of the endothelium.<sup>22-25</sup> Finally, a myriad of host-derived factors activate endothelial cells, including complement, cytokines, chemokines, serine proteases, fibrin, activated platelets and leukocytes, hyperglycemia, and/or changes in oxygenation or blood flow (see Table 1 and Figure 2 for an expanded list of host-derived mediators).

The endothelium responds in ways that differ according to the nature of the pathogen, host genetics, underlying comorbidity, age, gender, and the location of the vascular bed.<sup>82-91</sup> Endothelial cells may undergo structural changes, including nuclear vacuolization, cytoplasmic swelling, cytoplasmic fragmentation, denudation, and/or detachment.<sup>92</sup> Functional changes are more common and include shifts in the hemostatic balance, increased cell adhesion and leukocyte trafficking, altered vasomotor tone, loss of barrier function, and programmed cell death.

**Procoagulant properties.** Inflammatory mediators may interact with endothelial cells to induce a net procoagulant phenotype. Under *in vitro* conditions, the addition of LPS and/or cytokines to endothelial cells has been shown to decrease synthesis of TM, tissue-type plasminogen activator and heparan, to increase expression of TF and plasminogen activator inhibitor 1 (PAI-1), and to generate procoagulant microparticles.<sup>76,93-96</sup> The extent to which these changes occur in the intact endothelium is not entirely clear. In a recent study of patients with meningococemia, TM levels were reduced in dermal microvessels, an effect that would be predicted to yield decreased levels of activated protein C.<sup>42</sup> In a mouse model of endotoxemia, the administration of LPS resulted in reduction in total tissue TM antigen in the lung and brain, but not in the kidney,<sup>41</sup> suggesting that sepsis-associated changes in TM expression may vary between organs. While sepsis is associated with increased levels of PAI-1,<sup>84,97</sup> an endothelial source of PAI-1 has not been established. With few exceptions,<sup>46,47</sup> sepsis studies have consistently failed to demonstrate TF in the intact endothelium.

When the endothelium is viewed in the context of its native environment, additional properties emerge that may contribute to a procoagulant state. For example, activated endothelial cells attract platelets, monocytes, and neutrophils—cells that are capable of initiating or amplifying coagulation. Endothelial activation may

**Table 1. Treatment according to target(s)**

Therapies that target the host-pathogen interaction	Reference no.	Therapies that target coagulation	Reference no.
Antibiotics*	221	Antithrombin agents	
Anti-endotoxin antibodies†	16, 17, 222, 223	Heparin	157
Toll-like receptor or CD14 antagonists	224	Hirudin	45
Mediator-specific therapies that target inflammation		Antithrombin III†	145, 259
Anti-tumor necrosis factor antibodies†	225, 226	Inhibition of extrinsic pathway	
Platelet-activating factor acetylhydrolase	227	Anti-tissue factor antibodies	264
Bradykinin antagonists†	228, 229	Factor VII inhibition	162, 265
Anti-factor XII antibodies‡	230	Tissue factor pathway inhibitor†	161, 258, 290
Prostaglandin antagonists†	228, 231, 232	Inhibition of cofactor activity	
Anti-high mobility group 1 antibodies	233-235	Activated protein C§	10, 11
Anti-C5a antibodies	236, 237	Enhanced fibrinolysis	
Granulocyte-macrophage colony-stimulating factor inhibition	238, 239	Tissue plasminogen activator	266
Macrophage inhibitory factor inhibition	240, 241	Activated protein C§	10, 11
Anti-inflammatory agents (eg, interleukin 10)	242-244	Miscellaneous targets, amenable to inhibition	
Receptor antagonists		Apoptosis	139
Interleukin-1r antagonist†	12, 245	Transcription factors (eg, NF-κB)	188, 267
Soluble tumor necrosis factor receptor†	13	Ubiquitin-proteasome pathway	189
Platelet-activating factor receptor antagonist†	246, 247	Mechanical stretch, barotrauma§	147, 268
C5a receptor antagonists	248	Fever	269
Protease-activated receptor antagonists	249, 250	Hyperglycemia§	149, 270
Mediator nonspecific therapies that target inflammation		Elastase	271, 272
Cl-esterase inhibitor	49, 251, 252	Poly (ADP-ribose) synthetase (PARS)	273
Antioxidants	253, 254	Poly (ADP-ribose) polymerase 1	274, 275
Glucocorticoids§	148, 255-257	Nitric oxide	209, 210, 213
Activated protein C§	10, 11	P38 MAPK	196, 198
Tissue factor pathway inhibitor†	161, 258, 290	PKCδ, ζ	199, 276
Antithrombin III†	145, 259	Miscellaneous targets, amenable to enhancement	
Therapies that target cell-cell interactions		Oxygenation	173, 277-280
Antiplatelet agents	260-262	Blood flow and hemodynamic forces§	150, 281-284
Antiadhesion strategies	153, 263	Phospholipid oxidation products	142
		Soluble lectin-like domain of TM	285
		VEGF/Angiopoietin balance	286

References are not all-inclusive, but rather draw on a selection of basic, preclinical, early clinical and/or phase 3 clinical studies, as well as selected reviews.

\*Rapid institution of appropriate antibiotic therapy remains a mainstay in therapy of patients with severe sepsis.

†Phase 3 clinical trials have been conducted and demonstrated no survival benefit.

‡The major physiologic role of Factor XII is not to mediate coagulation activation, but rather to increase the rate and extent of prekallikrein activation, resulting in generation of bradykinin, increased profibrinolytic activity and inhibition of thrombin-mediated platelet activation.<sup>287-289</sup>

§Phase 3 clinical trials have been conducted and shown to improve survival. The degree to which treatment-related attenuation of endothelial cell activation contributed to overall benefit is unknown.

result in translocation of cell surface phospholipids that enhance binding of coagulation complexes. Endothelial cells undergoing apoptosis may express an increasingly procoagulant phenotype.<sup>98</sup> The development of a low blood-flow state in sepsis, whether secondary to reduced cardiac output, vasoconstriction, or occlusive lesions, may reduce clearance of activated serine proteases, thus promoting additional clotting.

As with other properties of the endothelium, the hemostatic balance is differentially regulated between vascular beds.<sup>31,75,77,99</sup> In a mouse model of endotoxemia, the systemic administration of LPS resulted in organ-specific deposition of fibrin in the kidney and adrenal gland.<sup>100</sup> In another study, LPS administration resulted in detectable levels of fibrin in the lung, but not the brain, of wild-type mice.<sup>41</sup> Still others have shown that LPS injection in wild-type mice yields increased fibrin levels in the kidney, liver, and myocardium, but not the lung.<sup>101</sup> In a baboon sepsis model, the administration of lethal doses of *E coli* resulted in increased fibrin deposition in the marginal zone and sinusoids of the spleen, the hepatic sinusoids, the glomeruli, and peritubular vessels of the kidney, but little or no fibrin in the portal vessels of the liver, cerebral cortex, skin, myocardium, or aorta.<sup>47</sup> The discrepant patterns of fibrin deposition in the above studies may be related to differences in the species/strain being analyzed, the type of sepsis model, and/or the nature of the fibrin assays. Nevertheless, when


taken together, the data are consistent in demonstrating an association between sepsis and organ-specific coagulation.

In genetic mouse models of hypercoagulability, sepsis results in an accentuated shift in the hemostatic balance. For example, in mice that carry a TM gene mutation that disrupts TM-dependent activation of protein C, LPS administration resulted in higher levels of fibrin deposition in the lung and kidney but not the brain, compared with wild-type mice.<sup>41</sup> In heterozygous ATIII-deficient mice, LPS challenge resulted in increased deposition of fibrin in the kidney, liver, and heart.<sup>101</sup> These studies demonstrate the importance of underlying genetics in modulating the sepsis phenotype.

**Proadhesive properties.** The endothelium responds to inflammatory mediators by expressing adhesion molecules on the cell surface, including P-selectin, E-selectin, ICAM-1, and VCAM-1. Collectively, these alterations result in increased rolling, strong adherence, and transmigration of leukocytes into underlying tissue. These changes are not universal, but rather occur locally in certain organs and segments of the vascular loop.<sup>102-108</sup> Activated endothelial cells also recruit increased numbers of platelets to the blood vessel wall.<sup>109-113</sup> The importance of adhesion molecules in mediating the sepsis phenotype is supported by studies in knock-out mice.<sup>114-116</sup>

**Vasomotor properties.** Vasomotor tone is regulated by a combination of endothelial-dependent and endothelial-independent mechanisms. Endothelial cells produce vasoactive molecules that regulate





**Figure 2. The endothelium as a therapeutic target.** An understanding of the endothelial response to pathogens provides a foundation for therapeutic design. For purposes of illustration and discussion, the temporal sequence of events is depicted from left to right. In sepsis, the endothelium is activated by LPS-mediated engagement of the toll-like receptor (TLR4) or by the interaction of inflammatory mediators (IL-6, TNF- $\alpha$ , IL-1, kinins, and C5a are shown) with their respective receptors (drawn as a single representative receptor). At the same time (or later during the sepsis cascade), the endothelium may be conditioned by other environmental factors, such as hypoxia, low blood flow, changes in temperature, acid-base/electrolyte abnormalities, and/or hyperglycemia. The interaction of extracellular mediators with their receptors leads to activation of downstream signaling pathways (including MAPK and PKC), which in turn promote posttranscriptional changes in cell function or alter gene expression profiles through a number of transcription factors, including NF- $\kappa$ B, GATA-2, and AP-1. The up-regulation of cell adhesion molecules on the surface of the endothelium (P-selectin, E-selectin, VCAM-1, and ICAM-1 are shown) promotes increased adhesion, rolling, and transmigration of circulating leukocytes. Leukocyte-endothelial interactions further modulate the phenotype of these cells. The release of cytokines from the endothelium results in additional activation of monocytes and endothelial cells. Increased expression of procoagulants (eg, TF) and/or reduced expression of anticoagulants (eg, TM, EPCR) promote increased thrombin generation and fibrin formation. Various components of the coagulation pathway (including serine proteases, fibrin, and platelets) may signal directly in the endothelium through protease-activated receptors (PAR-1 is shown). Changes in the expression of proapoptotic and antiapoptotic genes (along with a multitude of posttranscriptional changes) may result in a shift in balance toward programmed cell death. During the process of activation, NADPH oxidase may induce the formation of reactive oxygen species (ROS), nitric oxide (NO) is released, and cell permeability is increased. In keeping with the theme of spatial and temporal dynamics, the relative activity of the various pathways will vary between different endothelial cells and from one moment to the next. Not shown are the critical interactions between the endothelium and underlying extracellular matrix and parenchymal cells. Temp indicates temperature; ICAM-1, intracellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1; EC, endothelial cell; TF, tissue factor; TM, thrombomodulin; EPCR, endothelial protein C receptor; NO, nitric oxide; PGI<sub>2</sub>, prostacyclin. Receptors are labeled in light font.

arteriolar tone and contribute to blood pressure control. These include the vasodilators (nitric oxide [NO] and prostacyclin) and the vasoconstrictors (endothelin, thromboxane A<sub>2</sub>, and platelet-activating factor).<sup>117</sup> In sepsis, activated endothelium undergoes site-specific changes that impact the net balance of vasoconstrictor and vasodilatory properties.<sup>118</sup>

**Increased permeability.** In the intact vasculature, the endothelium forms a continuous, semipermeable barrier that varies in integrity and control for different vascular beds.<sup>119</sup> A central feature of the endothelium in sepsis is an increased permeability or loss of barrier function, resulting in a shift of circulating elements and tissue edema. TNF- $\alpha$  induces an increase in endothelial cell permeability both in vitro and in vivo.<sup>120-123</sup> Under in vitro conditions, thrombin also increases endothelial cell permeability, while TNF- $\alpha$  and thrombin act synergistically to induce barrier dysfunction in vitro.<sup>124</sup> Redistribution of fluid from the intravascular to the extravascular compartment may contribute to hypovolemia, hemoconcentration, and stasis of blood flow.

**Endothelial cell apoptosis.** Endothelial cell apoptosis is a highly regulated process.<sup>125</sup> Normally, only a small percentage (< 0.1%) of endothelial cells are apoptotic. Under in vitro conditions, certain pathogens are capable of inducing endothelial cell apoptosis.<sup>126</sup> The incubation of cultured endothelial cells with LPS has been reported to induce apoptosis in some,

but not all, studies.<sup>126-129</sup> LPS has been shown to up-regulate the Bcl-2 homologue, A1, and the zinc finger protein, A20, in cultured endothelial cells.<sup>130</sup> The sepsis cascade involves a large number of other mediators that may induce endothelial cell apoptosis, including TNF- $\alpha$ , IL-1, interferon, oxygen free radicals, and hypoxia.<sup>125,129,131</sup> The interaction between circulating cells and the endothelium may further augment proapoptotic signaling. For example, LPS-activated monocytes promote programmed cell death in endothelial cells by a combination of TNF- $\alpha$ -dependent and -independent mechanisms.<sup>132</sup>

Endothelial cell apoptosis results in an accentuated proinflammatory response. For example, under in vitro conditions, apoptotic endothelial cells mediate IL-1-dependent paracrine induction of ICAM-1 and VCAM-1,<sup>133</sup> increased production of reactive oxygen species (ROS), increased procoagulant activity,<sup>98</sup> decreased production of prostacyclin,<sup>134</sup> and activation of complement.<sup>135</sup> In addition, endothelial cells undergoing apoptosis demonstrate increased binding to nonactivated platelets.<sup>136</sup>

In a mouse model of endotoxemia, intraperitoneally delivered LPS resulted in widespread apoptosis of the endothelium.<sup>137</sup> In other studies, the intravenous administration of LPS in mice was shown to induce endothelial cell apoptosis in the lung, but not the liver, pointing to organ-specific differences in programmed cell death.<sup>138,139</sup>

#### Local versus systemic activation of the endothelium

The innate host response evolved as a locally operative mechanism to eradicate pathogens and necrotic tissue.<sup>140</sup> The endothelium orchestrates the local response by promoting the adhesion and transmigration of leukocytes, inducing thrombin generation and fibrin formation, altering local vasomotor tone, increasing permeability, and triggering programmed cell death.<sup>118</sup> The activation of coagulation serves a number of potential roles, including the walling off of pathogens, the activation of protease-activated receptors, and the extravascular stimulation of macrophage chemokine expression.<sup>141</sup> Normally, local and systemic negative feedback mechanisms are activated, dampening the response at distal sites.<sup>140,142</sup> Compartmentalization of the innate immune response limits collateral damage to the host and preserves integrity and adaptability of uninvolved endothelium. Hence, the endothelium as a whole is not locked into a single response but remains poised to deal with other insults. When the host response generalizes, it escapes the well-developed local checks and balances and results in a dysregulated, undirected inflammatory response. Under these conditions, widespread involvement of endothelium and monocytes/tissue macrophages, together with the more generalized activation of inflammation and coagulation, may lead to SIRS and MODS.

#### Link between endothelial cell dysfunction and MODS

Despite an increasing appreciation that inflammatory and coagulation cascades are activated in severe sepsis, little is known about the mechanisms that ultimately lead to organ dysfunction and death. The inflammatory and coagulation pathways and the various cell types are so tightly coupled that they cannot and should not be viewed as discrete entities in severe sepsis. Activation of the inflammatory cascade impacts the coagulation pathway, and vice versa. Activated monocytes affect the endothelium, and the reverse is also true. Dysfunction of any one organ has a downstream effect on all other organs. Therefore, the host response to sepsis is highly integrated, and the whole is far greater than the sum of its constituent parts (Figure 3).


Based on these considerations, how can we fairly assess the endothelium's role in mediating the sepsis phenotype? Available

evidence suggests that the function of the endothelium is altered in severe sepsis in ways that differ from one site of the vascular tree to another. These changes, while part of a larger, integrated host response, may help to initiate and perpetuate site-specific cycles of inflammation, coagulation, and cellular interactions that ultimately lead to microvascular occlusion, hypoxia, and organ dysfunction. To argue that the endothelium plays a more or less central role compared with the monocyte, or that inflammation is more or less important than the coagulation cascade in sepsis pathogenesis is misguided. Perhaps a more productive line of reasoning is as follows: the endothelium is a critical, but not the sole, component of the host response to sepsis; the endothelium is strategically located between blood and underlying tissue; the endothelium is a highly malleable and flexible cell layer; therefore, the endothelium is a potentially valuable target for sepsis therapy.

## The endothelium as a therapeutic target

### Therapeutic perspectives

Over the past decade, enormous resources have been expended on sepsis trials, with more than 10 000 patients enrolled in over 20 placebo-controlled, randomized phase 3 clinical trials.<sup>143,144</sup> Most of these therapies have failed to reduce mortality in patients with severe sepsis, including antiendotoxin, anticytokine, antiprostaglandin, antibradykinin, and anti-PAF strategies, ATIII, and TFPI.<sup>143,145,146</sup> At the time of this writing, a total of 5 phase 3 clinical trials have demonstrated improved survival in critically ill patients or patients with severe sepsis. These include the use of low tidal volume ventilation,<sup>147</sup> activated protein C,<sup>11</sup> low-dose glucocorticoids,<sup>148</sup> intensive insulin therapy,<sup>149</sup> and early goal-directed therapy.<sup>150</sup>



**Figure 3. The complexity of the host response to infection.** The host response to infection involves a wide array of cells and soluble mediators, which include but are not limited to monocytes, endothelial cells, and platelets and components of the complement, inflammatory, and coagulation cascades. Rather than showing the detailed connections, this figure is intended to convey the interdependent, redundant, and pleiotropic nature of the host response. Several factors modulate the phenotype, including the type of pathogen, and host factors such as genetic make-up, age, gender, and the health of other organ systems (liver and kidney are shown as examples). Normally, the host mechanisms are highly coordinated in both space and time to defend the host against pathogens. However, when the response is disproportionate to the threat (eg, excessive, sustained, or poorly localized), then the balance of power shifts in favor of the pathogen, resulting in the sepsis phenotype. Given the highly integrated and nonlinear nature of this response, it will be difficult to identify a single component whose therapeutic modulation will short-circuit the sepsis cascade and improve outcome. As long as the complexity of the sepsis response remains outside our grasp the best hope for therapeutic advances will depend on broad base targeting, in which multiple components are targeted at the same time.

### Strategies for targeting the endothelium

In principle, there are 2 strategies for attenuating the endothelial response in sepsis. One is to target nonendothelial components of the host response, including soluble mediators or other cell types (eg, leukocytes, platelets), which negatively modulate endothelial cell function. The other is to target endothelial components (eg, cell surface receptors, signaling pathways, transcriptional networks, or endothelial cell gene products) that are involved in mediating the sepsis phenotype (Figure 2; Table 1). The targets that are listed in Table 1 are derived from a combination of basic and clinical studies. While a number of these therapies have reached phase 3 clinical trials, others are in preclinical or early-phase clinical stages. The extent to which these latter targets will translate into clinical efficacy remains to be seen.

**Antimediator therapy.** Several efforts have been made to target LPS or inflammatory mediators that directly activate endothelial cells either at the level of the extracellular factor or its receptor. In large phase 3 clinical trials, the use of specific antimediator therapy has consistently failed to improve survival in patients with severe sepsis.<sup>146,151,152</sup>

**Antiadhesion therapy.** The interaction of circulating cells with the endothelium is likely to play an important role in the host response to infection. Several strategies have been used to inhibit leukocyte-endothelial cell interactions in animal models of sepsis, including the use of monoclonal antibodies.<sup>153</sup> Moreover, nonactivated platelets roll on stimulated endothelium, in a process that involves P-selectin and E-selectin,<sup>154,155</sup> suggesting that therapy aimed at these cell adhesion molecules may also attenuate platelet-endothelial interactions. Activated platelets have been shown to adhere to the endothelium through a GPIIb/IIIa-dependent mechanism,<sup>156</sup> pointing to a potential role for GPIIb/IIIa inhibitors in sepsis. At the present time, antiadhesion therapy in sepsis remains investigational.

**Anticoagulant therapy.** Several natural anticoagulant molecules have been studied in nonhuman primate models of sepsis. Heparin and active-site-blocked factor Xa inhibited the activation of coagulation, but did not protect against organ dysfunction or mortality.<sup>157,158</sup> These results suggest that activation of the coagulation cascade is not in and of itself sufficient to induce mortality in this syndrome. In contrast to agents that inhibit thrombin activity or thrombin generation, the administration of active-site-blocked factor VIIa, ATIII, activated protein C, or TFPI blocked activation of the coagulation and inflammatory pathways, reduced organ damage, and prevented lethality in a baboon model of sepsis.<sup>159-162</sup> The anti-inflammatory effect of these agents is related, at least in part, to their ability to block protease-activated receptor-mediated signaling and/or to activate protective pathways within the endothelium.<sup>163-165</sup> Together with the results of the failed anticytokine/antimediator trials, these data suggest, but by no means prove, that mortality in severe sepsis is linked to the combined activation of the coagulation and proinflammatory pathways.

The therapeutic potential of activated protein C was evidenced in the recent phase 3 Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial, in which the administration of human recombinant activated protein C (drotrecogin alfa [activated]) to patients with severe sepsis resulted in reduced mortality.<sup>11</sup> A total of 1690 patients with a diagnosis of severe sepsis were randomized to receive either drotrecogin alfa (activated) or placebo. There was a statistically significant reduction in 28-day all-cause mortality (24.7% vs 30.8% in the treatment and placebo groups, respectively,  $P < .005$ ).<sup>11</sup> The

PROWESS trial is the first published clinical trial to demonstrate a survival benefit in patients with severe sepsis.

In contrast to the promising results of preclinical and early phase 1/2 studies, phase 3 clinical trials with ATIII or TFPI failed to demonstrate improved survival in patients with severe sepsis.<sup>145,290</sup> One possible explanation for these findings relates to study design. For example, patients in the phase 3 clinical trials may have received suboptimal doses of ATIII and/or TFPI. Moreover, in the ATIII study, a potential benefit of the drug may have been obscured by the concomitant administration of heparin.<sup>166,167</sup> An alternative explanation is that activated protein C has unique biologic effects that set it apart from ATIII and TFPI in humans with severe sepsis (as distinct from the baboon model of sepsis). Indeed, while TFPI and ATIII are likely to indirectly exert their anti-inflammatory effect through protease-activated receptors (to date, there is no evidence of an ATIII receptor), activated protein C binds to and activates a unique receptor, the endothelial protein C receptor (EPCR), which is expressed on the surface of endothelial cells and possibly monocytes. The interaction between activated protein C and its receptor has been implicated in its profound anti-inflammatory and antiapoptotic function (see "Note added in proof").<sup>164</sup>

**Antiapoptosis therapy.** As discussed earlier, apoptosis may play a critical role in mediating the sepsis phenotype. Interestingly, inhibition of apoptosis represents a common thread in established sepsis therapies. For example, activated protein C has been shown to inhibit apoptosis in cultured endothelial cells by mechanisms that may include transcriptional down-regulation of the proapoptotic genes calcitriol and TRMP-2, and induction of the antiapoptotic genes A1 Bcl-2 homolog and inhibitor of apoptosis (IAP) homolog B.<sup>164</sup> The maintenance of blood flow and hence shear stress may be an important inhibitor of endothelial cell apoptosis,<sup>168</sup> and the benefits of early goal-directed therapy may reflect, at least in part, the protective effect of hemodynamics on endothelial cell function.<sup>150</sup> Hyperglycemia has been reported to promote endothelial cell apoptosis.<sup>169,170</sup> Moreover, insulin promotes Akt-dependent endothelial cell survival.<sup>171</sup> In light of these findings, it is interesting to speculate that intensive insulin therapy and tight blood glucose control in critically ill patients has a protective (prosurvival) effect on the endothelium.<sup>149</sup>

Hypoxia has been shown to induce programmed cell death in endothelial cells, thus emphasizing the importance of maintaining adequate oxygenation.<sup>172,173</sup> Other antiapoptotic strategies that may warrant consideration include statins,<sup>174</sup> antioxidants, growth factors,<sup>175</sup> and caspase inhibitors.<sup>139</sup>

**Transcription factors as targets.** Several transcription factors in the endothelium have been implicated in the host response to infection, including NF- $\kappa$ B,<sup>25,176-179</sup> epithelium-specific Ets factor-1 (ESE-1),<sup>180</sup> activator protein-1 (AP-1),<sup>181-183</sup> GATA-2,<sup>60,184,185</sup> and Egr-1.<sup>186</sup> In addition, LPS administration in rodents has been shown to down-regulate DNA-binding activity of Sp1 and AP-2.<sup>187</sup>

Of the various transcription factors involved in mediating the sepsis phenotype, NF- $\kappa$ B has received the most attention as a potential therapeutic target. In a mouse model of endotoxemia, the intravenous somatic gene transfer with I $\kappa$ B $\alpha$  resulted in increased survival.<sup>177</sup> In a rat model of sepsis, the systemic administration of pyrrolidine dithiocarbamate inhibited NF- $\kappa$ B-mediated gene expression of TNF- $\alpha$ , cyclooxygenase-2 (COX-2), and ICAM-1.<sup>188</sup> More selective NF- $\kappa$ B inhibitors, such as the antibacterial peptide PR39, may hold greater promise.<sup>189</sup>

ATIII and activated protein C have each been shown to inhibit NF- $\kappa$ B activation of endothelial cells.<sup>163,164</sup> A recent study demonstrated that low-dose glucocorticoids reduce mortality in patients with severe sepsis.<sup>148</sup> The beneficial effects of steroids may be related, in part, to an attenuation of NF- $\kappa$ B activity.<sup>184,190</sup>

As an important caveat, NF- $\kappa$ B has been shown to attenuate TNF- $\alpha$ -mediated apoptosis of endothelial cells, perhaps through the induction of cytoprotective proteins such as IAPs, Bcl-2-like factors, and A20.<sup>191</sup> Moreover, the selective blockade of NF- $\kappa$ B sensitized endothelial cells to the proapoptotic effects of TNF- $\alpha$ .<sup>192</sup> These observations suggest that NF- $\kappa$ B may play a protective role during the sepsis continuum and underscore the need for caution in developing anti-NF- $\kappa$ B therapies.

**Signaling pathways as targets.** The p38 mitogen-activated protein kinase (MAPK) signaling pathway is believed to play an important role in mediating proinflammatory responses and endothelial cell apoptosis.<sup>175,193,194</sup> Mice that are null for MAPK kinase 2, a downstream p38 MAPK target, demonstrate increased resistance to LPS, an effect that is explained by reduced TNF- $\alpha$  production.<sup>195</sup> Several studies have targeted p38 MAPK signaling in animal models, with mixed results.<sup>196,197</sup> Interestingly, in a human model of endotoxemia, the oral administration of a new p38 MAPK inhibitor reduced cytokine production and leukocyte responses.<sup>198</sup> The extent to which the treatment impacted on endothelial cell dysfunction was not addressed.

Novel and atypical isoforms of protein kinase C (PKC) have also been implicated endothelial cell activation. Under in vitro conditions, thrombin-mediated induction of ICAM-1 in endothelial cells is dependent on a PKC- $\delta$ -NF- $\kappa$ B signaling pathway, whereas TNF- $\alpha$ -mediated stimulation of ICAM-1 involves PKC- $\zeta$ -NF- $\kappa$ B.<sup>56,199</sup> Thrombin stimulation of VCAM-1 in endothelial cells is mediated by PKC- $\delta$ -NF- $\kappa$ B and PKC- $\zeta$ -GATA-2 signaling pathways.<sup>200</sup> PKC- $\zeta$  has also been shown to mediate TNF- $\alpha$  stimulation of NADPH oxidase-derived ROS in endothelial cells.<sup>201</sup> Compared with wild-type mice, LPS administration to PKC- $\zeta$ <sup>-/-</sup> mice resulted in significantly less NF- $\kappa$ B activation in the lung, but not the liver.<sup>202</sup> These latter results suggest that the PKC- $\zeta$  isoform plays an important role in mediating the host response in select organs and may represent a valuable target for site-specific therapy in severe sepsis.

**Nitric oxide synthase (NOS) inhibitors.** Sepsis is associated with increased inducible NOS (iNOS) activity and decreased endothelial NOS (eNOS) activity.<sup>203-205</sup> However, the relative role of iNOS and eNOS in mediating the sepsis phenotype remains unclear. In genetic mouse models, the absence of iNOS or eNOS does not significantly alter the sepsis phenotype.<sup>206,207</sup> Indeed, the chronic overexpression of eNOS in the endothelium of mice resulted in increased resistance to LPS-induced hypotension and death.<sup>208</sup> In some studies, the use of NOS inhibitors yielded beneficial results,<sup>209-211</sup> whereas other studies reported the opposite findings.<sup>212</sup> In a rabbit model of sepsis, the administration of L-arginine, but not L-NAME (N(G)-nitro-L-arginine methyl ester), attenuated LPS-mediated endothelial cell injury.<sup>213</sup> LPS-mediated induction of platelet-endothelial interactions in mice has been shown to be attenuated by NO donor and exacerbated by NOS inhibitor or eNOS deficiency, suggesting a beneficial effect of eNOS-derived NO.<sup>214</sup> Further work is required before considering NOS inhibition therapy in sepsis.

### Therapeutic challenges

Many reasons have been postulated to explain the long history of failed clinical trials in sepsis. These include inapplicability of results from animal models of sepsis, nonuniformity of supportive care, heterogeneity in patient populations, confounding effects of cointervention, inappropriate timing, and poor choice of outcome measures.<sup>143,146,151,152,166,215,216</sup> An underemphasized explanation relates to the complexity of the host response. These themes are important to consider when approaching the endothelium as a therapeutic target.

**Timing.** Sepsis represents a continuum in clinical and pathologic severity. In sepsis trials, the choice of inclusion and exclusion criteria



may significantly influence the outcome. For example, at one end of the spectrum, the inclusion of low-risk patients may hide an otherwise beneficial response. In these individuals, the adverse effects of treatment (eg, anticoagulant-mediated bleeding) may outweigh any small benefit. Another important consideration is the adaptive nature of the host response. As long as the overall response is protective (eg, during the early stages of the sepsis continuum), targeted therapy may have no effect, or even a negative impact on survival.<sup>144</sup> At the other end of the spectrum, patients who present with late-stage disease may be relatively resistant to therapy. Sepsis-induced cascades that were once amenable to therapeutic intervention may no longer be responsive. When designing therapies that target the endothelium, it will be important to define the optimal timing and spectrum of disease severity.

**Complexity of the host response.** Traditionally, reductionist approaches have been applied to an understanding of sepsis pathophysiology. Indeed, the vast majority of basic studies in this field have focused on isolated and specific mechanisms of the host response. These data have given rise to linear models of pathophysiology, which in turn have guided the choice of therapeutic targets. The notion that the various components of the host response are aligned in series predicts that the attenuation of any one component (eg, TNF- $\alpha$ ) will abort the sepsis cascade. This “domino-type model” is giving way to a more realistic paradigm of nonlinear complexity, in which the various cell types, inflammatory mediators, coagulation factors, cell surface receptors, intracellular signaling pathways, transcription factors, and genes interact as part of spatially and temporally coupled networks.<sup>80,217,218</sup> The nonlinear dynamics of the host response may help to explain, at least in part, the disappointing results of single-target therapy trials in severe sepsis.

One way to deal with the inherent complexity of the host response is to develop broad-base targeting schemes in which multiple components are attenuated at once, for example the inflammatory and coagulation cascades. It is perhaps by casting a wider “therapeutic net” that activated protein C succeeded, where so many other agents before it have failed. Although the precise mechanism(s) by which drotrecogin alfa (activated) improved survival in these patients is not known, several lines of evidence point to a multifaceted role of this agent in inhibiting the proinflammatory and procoagulant response, promoting fibrinolysis, and attenuating the activation of endothelial cells and white blood cells.<sup>38,219,220</sup>

An alternative approach is to target a nonredundant component of the host response that is central to the initiation and perpetuation of the sepsis phenotype. Examples might include a single function of the endothelium (eg, apoptosis), or a single transcription factor (eg, NF- $\kappa$ B). However, in designing such strategies, it is important that we acknowledge the unpredictable behavior of complex nonlinear systems and readjust our expectations accordingly. While in theory the host response to infection (for any one patient at a single time point) may be modeled by a highly complex series of nonlinear equations, these formulas are not only elusive, but are likely to be exquisitely sensitive to initial conditions. As a result, single-component targeting may not only fail to modulate the host response, but may have unintended, deleterious consequences. An important scientific challenge for the 21st century is to learn how to leverage nonlinear interactions for mechanistic and therapeutic gain. Future progress in understanding complex networks will rely

both on improved readouts and more complete statistical and mathematical tools, including advanced clustering techniques, other data mining and pattern recognition strategies, Bayesian techniques, differential equations, and simulation tools. By studying and embracing more realistic biologic models that involve complex networks, we may improve our capacity to reconfigure the host response in our favor.

**Implications for clinical trials.** In clinical trials, patients may be alike, but they are never identical. From a therapeutic standpoint, what may save one patient may actually harm another. Moreover, a therapeutic intervention that benefits a given patient at one moment in time may be deleterious at another point in time. Thus, the optimal therapy for sepsis is highly patient and time dependent. However, until we can better characterize the complex behavior of the host response, we are restricted to classic randomized control trial design, in which a single intervention is tested in a heterogeneous group of patients. An important goal, which can be achieved only through large clinical trials, is to identify subgroups of patients that appear to benefit from treatment. This information may then be used to design new preclinical/clinical studies. Such an approach should help to reduce patient heterogeneity (or noise) and to develop more tailored therapy, for example, against one or another component of the endothelial response or toward specific vascular bed(s).

## Conclusions

Despite new information about the pathophysiology and treatment of severe sepsis, this disorder continues to be associated with an unacceptably high mortality rate. Future breakthroughs will require a conceptual shift that emphasizes relationships between the various mediators and cells involved in host response. The endothelium is key in initiating, perpetuating, and modulating the host response to infection. Additional studies promise to provide new insight into the endothelium, not as an isolated mechanism of sepsis pathophysiology, but rather as the coordinator of a far more expansive, spatially and temporally orchestrated response.

*Note added in proof.* A recent study demonstrated that activated protein C signals through PAR-1 in cultured endothelial cells, by an EPCR-dependent mechanism.<sup>291</sup> Consistent with these results, both EPCR and PAR-1 were shown to be required for mediating the cytoprotective function of activated protein C in hypoxic cultured human brain endothelial cells and in a stroke model of mice.<sup>292</sup> Collectively, these findings suggest that activated protein C signals through the PAR-1 receptor both in vitro and in vivo. Since PAR-1 is also a receptor for thrombin, these studies raise interesting questions as to how two distinct ligands, namely activated protein C and thrombin, mediate opposing PAR-1 responses (eg, protective and proinflammatory responses, respectively).

## Acknowledgments

I thank Derek Angus, John Marshall, Wes Ely, and Ary Goldberger for their helpful input.

## References

1. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. *JAMA*. 1995;273:117-123.
2. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest*. 1992;101:1644-1655.
3. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia—United States, 1979-1987. *JAMA*. 1990;263:937-938.
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United



- States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med.* 2001;29:1303-1310.
5. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. *JAMA.* 1995;274:968-974.
  6. Damas P, Canivet JL, de Groote D, et al. Sepsis and serum cytokine concentrations. *Crit Care Med.* 1997;25:405-412.
  7. Thijs LG, Hack CE. Time course of cytokine levels in sepsis. *Intensive Care Med.* 1995;21(suppl 2):S258-S263.
  8. Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. *Chest.* 1993;103:565-575.
  9. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. *Chest.* 2001;120:915-922.
  10. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. *Crit Care Med.* 2001;29:2051-2059.
  11. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med.* 2001;344:699-709.
  12. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. *Crit Care Med.* 1997;25:1115-1124.
  13. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. *N Engl J Med.* 1996;334:1697-1702.
  14. Levi M, ten Cate H. Disseminated intravascular coagulation. *N Engl J Med.* 1999;341:586-592.
  15. Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. *J Crit Care.* 2001;16:167-177.
  16. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESSTrial Study Group. *Ann Intern Med.* 1994;121:1-5.
  17. Angus DC, Birmingham MC, Balk RA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. *JAMA.* 2000;283:1723-1730.
  18. Opal SM, Huber CE. Bench-to-bedside review: toll-like receptors and their role in septic shock. *Crit Care.* 2002;6:125-136.
  19. Janeway CA Jr, Medzhitov R. Innate immune recognition. *Annu Rev Immunol.* 2002;20:197-216.
  20. Medzhitov R. Toll-like receptors and innate immunity. *Nature Rev Immunol.* 2001;1:135-145.
  21. Triantafyllou M and Triantafyllou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. *Trends Immunol.* 2002;23:301-304.
  22. Faure E, Thomas L, Xu H, et al. Bacterial lipopolysaccharide and IFN-gamma induce toll-like receptor 2 and toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. *J Immunol.* 2001;166:2018-2024.
  23. Henneke P, Golenbock DT. Innate immune recognition of lipopolysaccharide by endothelial cells. *Crit Care Med.* 2002;30:S207-S213.
  24. Zhang FX, Kirschning CJ, Mancinelli R, et al. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. *J Biol Chem.* 1999;274:7611-7614.
  25. Zhao B, Bowden RA, Stavchansky SA, Bowman PD. Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays. *Am J Physiol Cell Physiol.* 2001;281:C1587-C1595.
  26. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. *Chest.* 1997;112:235-243.
  27. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. *Crit Care Med.* 1996;24:1125-1128.
  28. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. *Shock.* 2001;16:83-96.
  29. van der Poll T, van Deventer SJ. Cytokines and anti-cytokines in the pathogenesis of sepsis. *Infect Dis Clin North Am.* 1999;13:413-426.
  30. Pinsky MR. Immune balance in critically ill patients. *Arch Immunol Ther Exp.* 2000;48:439-442.
  31. Aird WC. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. *Crit Care Med.* 2001;29:S28-S35.
  32. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. *Proc Natl Acad Sci U S A.* 1977;74:5260-5264.
  33. Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. *Blood.* 1990;76:731-736.
  34. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. *J Clin Invest.* 1993;92:1207-1212.
  35. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. *Science.* 1991;253:909-912.
  36. Broze GJ Jr. Tissue factor pathway inhibitor. *Thromb Haemost.* 1995;74:90-93.
  37. Rosenberg RD. Biochemistry of heparin-antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. *Am J Med.* 1989;87:2S-9S.
  38. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. *Crit Care Med.* 2001;29:S48-S51;discussion 51-42.
  39. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. *Semin Thromb Hemost.* 1998;24:33-44.
  40. White B, Perry D. Acquired antithrombin deficiency in sepsis. *Br J Haematol.* 2001;112:26-31.
  41. Weiler H, Lindner V, Kerlin B, et al. Characterization of a mouse model for thrombomodulin deficiency. *Arterioscler Thromb Vasc Biol.* 2001;21:1531-1537.
  42. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. *N Engl J Med.* 2001;345:408-416.
  43. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. *Thromb Haemost.* 1983;49:5-7.
  44. Collins PW, Noble KE, Reittie JR, et al. Induction of tissue factor expression in human monocyte/endothelium cocultures. *Br J Haematol.* 1995;91:963-970.
  45. Pernerstorfer T, Hollenstein U, Hansen JB, et al. Lepirudin blunts endotoxin-induced coagulation activation. *Blood.* 2000;95:1729-1734.
  46. Todoroki H, Nakamura S, Higure A, et al. Neutrophils express tissue factor in a monkey model of sepsis. *Surgery.* 2000;127:209-216.
  47. Drake TA, Cheng J, Chang A, Taylor FB Jr. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal *Escherichia coli* sepsis. *Am J Pathol.* 1993;142:1458-1470.
  48. Carson SD, Johnson DR. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. *Blood.* 1990;76:361-367.
  49. Jansen PM, Eisele B, de Jong IW, et al. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. *J Immunol.* 1998;160:475-484.
  50. Coughlin SR. How the protease thrombin talks to cells. *Proc Natl Acad Sci U S A.* 1999;96:11023-11027.
  51. Coughlin SR. Thrombin signalling and protease-activated receptors. *Nature.* 2000;407:258-264.
  52. Vouret-Craviari V, Boquet P, Pouyssegur J, Van Obberghen-Schilling E. Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. *Mol Biol Cell.* 1998;9:2639-2653.
  53. Malik AB, Fenton JW 2nd. Thrombin-mediated increase in vascular endothelial permeability. *Semin Thromb Hemost.* 1992;18:193-199.
  54. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. *J Biol Chem.* 1999;274:23969-23976.
  55. Sugama Y, Tirupathi C, Offakidevi K, et al. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. *J Cell Biol.* 1992;119:935-944.
  56. Rahman A, Anwar KN, True AL, Malik AB. Thrombin-induced p65 homodimer binding to downstream NF-kappa B site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion. *J Immunol.* 1999;162:5466-5476.
  57. Lorant DE, Patel KD, McIntyre TM, et al. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. *J Cell Biol.* 1991;115:223-234.
  58. Kaplanski G, Marin V, Fabrigoule M, et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). *Blood.* 1998;92:1259-1267.
  59. Kaplanski G, Fabrigoule M, Boulay V, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. *J Immunol.* 1997;158:5435-5441.
  60. Minami T, Aird WC. Thrombin stimulation of the vascular cell adhesion molecule-1 promoter in endothelial cells is mediated by tandem nuclear factor-kappa B and GATA motifs. *J Biol Chem.* 2001;276:47632-47641.
  61. Vischer UM, Barth H, Wollheim CB. Regulated von Willebrand factor secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells. *Arterioscler Thromb Vasc Biol.* 2000;20:883-891.
  62. Ellis CA, Malik AB, Gilchrist A, et al. Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen-activated protein kinase pathway. *J Biol Chem.* 1999;274:13718-13727.
  63. Zimmerman GA, McIntyre TM, Prescott SM. Production of platelet-activating factor by human vascular endothelial cells: evidence for a requirement for specific agonists and modulation by prostacyclin. *Circulation.* 1985;72:718-727.
  64. Ueno A, Murakami K, Yamanouchi K, Watanabe M, Kondo T. Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells. *Immunology.* 1996;88:76-81.
  65. Colotta F, Sciacca FL, Sironi M, et al. Expression of monocyte chemoattractant protein-1 by monocytes and endothelial cells exposed to thrombin. *Am J Pathol.* 1994;144:975-985.
  66. Duhamel-Clerin E, Orvain C, Lanza F, Cazenave JP, Klein-Soyer C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells.

- Arterioscler Thromb Vasc Biol. 1997;17:1931-1938.
67. Rottingen JA, Enden T, Camerer E, Iversen JG, Prydz H. Binding of human factor VIIa to tissue factor induces cytosolic Ca<sup>2+</sup> signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. *J Biol Chem*. 1995;270:4650-4660.
  68. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of pro-tease-activated receptor 2 by factor VIIa. *Proc Natl Acad Sci U S A*. 2000;97:5255-5260.
  69. Camerer E, Kataoka H, Kahn M, Lease K, Coughlin SR. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. *J Biol Chem*. 2002;277:16081-16087.
  70. Bono F, Schaeffer P, Herault JP, et al. Factor Xa activates endothelial cells by a receptor cascade between EPR-1 and PAR-2. *Arterioscler Thromb Vasc Biol*. 2000;20:E107-E112.
  71. Gorlatov S, Medved L. Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: mapping of the receptor-binding site in the NH<sub>2</sub>-terminal portions of the fibrin beta chains. *Biochemistry*. 2002;41:4107-4116.
  72. Qi J, Goralnick S, Kreuzer DL. Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. *Blood*. 1997;90:3595-3602.
  73. Wolinsky H. A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis. *Circ Res*. 1980;47:301-311.
  74. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. *Blood*. 1998;91:3527-3561.
  75. Gross PL, Aird WC. The endothelium and thrombosis. *Semin Thromb Hemost*. 2000;26:463-478.
  76. Bombeli T, Mueller M, Haerberli A. Anticoagulant properties of the vascular endothelium. *Thromb Haemost*. 1997;77:408-423.
  77. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. *N Engl J Med*. 1999;340:1555-1564.
  78. Stevens T, Rosenberg R, Aird W, et al. NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. *Am J Physiol Cell Physiol*. 2001;281:C1422-C1433.
  79. Gerritsen ME. Functional heterogeneity of vascular endothelial cells. *Biochem Pharmacol*. 1987;36:2701-2711.
  80. Aird WC. Endothelial cell dynamics and complexity theory. *Crit Care Med*. 2002;30:S180-S185.
  81. Volk T, Kox WJ. Endothelium function in sepsis. *Inflamm Res*. 2000;49:185-198.
  82. Cariou A, Chiche JD, Charpentier J, Dhainaut JF, Mira JP. The era of genomics: impact on sepsis clinical trial design. *Crit Care Med*. 2002;30:S341-S348.
  83. Yamamoto K, Shimokawa T, Yi H, et al. Aging accelerates endotoxin-induced thrombosis: increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. *Am J Pathol*. 2002;161:1805-1814.
  84. Mavrommatis AC, Theodoridis T, Economou M, et al. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. *Intensive Care Med*. 2001;27:1853-1859.
  85. Kumar A, Short J, Parrillo JE. Genetic factors in septic shock. *JAMA*. 1999;282:579-581.
  86. Mira JP, Cariou A, Grall F, et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. *JAMA*. 1999;282:561-568.
  87. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. *Lancet*. 1997;349:1912-1913.
  88. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. *Nat Genet*. 2000;25:187-191.
  89. Arnalich F, Lopez-Maderuelo D, Codoceo R, et al. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. *Clin Exp Immunol*. 2002;127:331-336.
  90. Hermans PW, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. *Meningococcal Research Group*. *Lancet*. 1999;354:556-560.
  91. Nadel S. Helping to understand studies examining genetic susceptibility to sepsis. *Clin Exp Immunol*. 2002;127:191-192.
  92. Vallet B, Wiel E. Endothelial cell dysfunction and coagulation. *Crit Care Med*. 2001;29:S36-S41.
  93. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. *Proc Natl Acad Sci U S A*. 1986;83:4533-4537.
  94. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. *J Clin Invest*. 1999;104:93-102.
  95. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. *J Clin Invest*. 1987;79:124-130.
  96. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. *J Biol Chem*. 1988;263:5797-5803.
  97. Green J, Doughty L, Kaplan SS, Sasser H, Carcillo JA. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. *Thromb Haemost*. 2002;87:218-223.
  98. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. *Blood*. 1997;89:2429-2442.
  99. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prothrombotic state. *J Clin Invest*. 1998;101:1983-1991.
  100. Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. *J Clin Invest*. 1996;97:2440-2451.
  101. Yanada M, Kojima T, Ishiguro K, et al. Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. *Blood*. 2002;99:2455-2458.
  102. Eppihimer MJ, Wolitzky B, Anderson DC, Labow MA, Granger DN. Heterogeneity of expression of E- and P-selectins in vivo. *Circ Res*. 1996;79:560-569.
  103. Panes J, Perry MA, Anderson DC, et al. Regional differences in constitutive and induced ICAM-1 expression in vivo. *Am J Physiol*. 1995;269:H1955-H1964.
  104. Mulligan MS, Vaporciyan AA, Miyasaka M, Tamatani T, Ward PA. Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. *Am J Pathol*. 1993;142:1739-1749.
  105. Lopez S, Prats N, Marco AJ. Expression of E-selectin, P-selectin, and intercellular adhesion molecule-1 during experimental murine listeriosis. *Am J Pathol*. 1999;155:1391-1397.
  106. Bauer P, Lush CW, Kvietzky PR, Russell JM, Granger DN. Role of endotoxin in the expression of endothelial selectins after cecal ligation and perforation. *Am J Physiol Regul Integr Comp Physiol*. 2000;278:R1140-R1147.
  107. Lush CW, Cepinskas G, Sibbald WJ, Kvietzky PR. Endothelial E- and P-selectin expression in iNOS-deficient mice exposed to polymicrobial sepsis. *Am J Physiol Gastrointest Liver Physiol*. 2001;280:G291-G297.
  108. Henninger DD, Panes J, Eppihimer M, et al. Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. *J Immunol*. 1997;158:1825-1832.
  109. Sheu JR, Hung WC, Wu CH, et al. Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. *Circulation*. 1999;99:3056-3062.
  110. Shibazaki M, Kawabata Y, Yokochi T, et al. Complement-dependent accumulation and degradation of platelets in the lung and liver induced by injection of lipopolysaccharides. *Infect Immun*. 1999;67:5186-5191.
  111. Shibazaki M, Nakamura M, Endo Y. Biphasic, organ-specific, and strain-specific accumulation of platelets induced in mice by a lipopolysaccharide from *Escherichia coli* and its possible involvement in shock. *Infect Immun*. 1996;64:5290-5294.
  112. Katayama T, Ikeda Y, Handa M, et al. Immunoneutralization of glycoprotein Ibalph attenuates endotoxin-induced interactions of platelets and leukocytes with rat venular endothelium in vivo. *Circ Res*. 2000;86:1031-1037.
  113. Tsujikawa A, Kiryu J, Yamashiro K, et al. Interactions between blood cells and retinal endothelium in endotoxic sepsis. *Hypertension*. 2000;36:250-258.
  114. Munoz FM, Hawkins EP, Bullard DC, Beaudet AL, Kaplan SL. Host defense against systemic infection with *Streptococcus pneumoniae* is impaired in E-, P-, and E-/P-selectin-deficient mice. *J Clin Invest*. 1997;100:2099-2106.
  115. Steeber DA, Tang ML, Green NE, et al. Leukocyte entry into sites of inflammation requires overlapping interactions between the L-selectin and ICAM-1 pathways. *J Immunol*. 1999;163:2176-2186.
  116. Matsukawa A, Lukacs NW, Hogaboam CM, et al. Mice genetically lacking endothelial selectins are resistant to the lethality in septic peritonitis. *Exp Mol Pathol*. 2002;72:68-76.
  117. Wanecek M, Weitzberg E, Rudehill A, Oldner A. The endothelin system in septic and endotoxin shock. *Eur J Pharmacol*. 2000;407:1-15.
  118. McCuskey RS, Urbaschek R, Urbaschek B. The microcirculation during endotoxemia. *Cardiovasc Res*. 1996;32:752-763.
  119. Stevens T, Garcia JG, Shasby DM, Bhattacharya J, Malik AB. Mechanisms regulating endothelial cell barrier function. *Am J Physiol Lung Cell Mol Physiol*. 2000;279:L419-L422.
  120. Ferro T, Neumann P, Gertzberg N, Clements R, Johnson A. Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha. *Am J Physiol Lung Cell Mol Physiol*. 2000;278:L1107-L1117.
  121. Ferro TJ, Gertzberg N, Selden L, Neumann P, Johnson A. Endothelial barrier dysfunction and p42 oxidation induced by TNF-alpha are mediated by nitric oxide. *Am J Physiol*. 1997;272:L979-L988.
  122. Goldblum SE, Ding X, Campbell-Washington J. TNF-alpha induces endothelial cell F-actin depolymerization, new actin synthesis, and barrier dysfunction. *Am J Physiol*. 1993;264:C894-C905.
  123. Johnson J, Meyrick B, Jesmok G, Brigham KL. Human recombinant tumor necrosis factor alpha infusion mimics endotoxemia in awake sheep. *J Appl Physiol*. 1989;66:1448-1454.
  124. Tirupathi C, Naqvi T, Sandoval R, Mehta D, Malik AB. Synergistic effects of tumor necrosis factor-alpha and thrombin in increasing endothelial permeability. *Am J Physiol Lung Cell Mol Physiol*. 2001;281:L958-L968.
  125. Stefanec T. Endothelial apoptosis: could it have a role in the pathogenesis and treatment of disease? *Chest*. 2000;117:841-854.
  126. Hotchkiss RS, Tinsley KW, Swanson PE, Karl IE.

- Endothelial cell apoptosis in sepsis. *Crit Care Med.* 2002;30:S225-S228.
127. Bannerman DD, Sathyamoorthy M, Goldblum SE. Bacterial lipopolysaccharide disrupts endothelial monolayer integrity and survival signaling events through caspase cleavage of adherens junction proteins. *J Biol Chem.* 1998;273:35371-35380.
  128. Choi KB, Wong F, Harlan JM, et al. Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway. *J Biol Chem.* 1998;273:20185-20188.
  129. Messmer UK, Briner VA, Pfeilschifter J. Tumor necrosis factor- $\alpha$  and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells. *Kidney Int.* 1999;55:2322-2337.
  130. Hu X, Yee E, Harlan JM, Wong F, Karsan A. Lipopolysaccharide induces the antiapoptotic molecules, A1 and A20, in microvascular endothelial cells. *Blood.* 1998;92:2759-2765.
  131. Polunovsky VA, Wendt CH, Ingbar DH, Peterson MS, Bitterman PB. Induction of endothelial cell apoptosis by TNF  $\alpha$ : modulation by inhibitors of protein synthesis. *Exp Cell Res.* 1994;214:584-594.
  132. Lindner H, Holler E, Ertl B, et al. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines. *Blood.* 1997;89:1931-1938.
  133. Hebert MJ, Gullans SR, Mackenzie HS, Brady HR. Apoptosis of endothelial cells is associated with paracrine induction of adhesion molecules: evidence for an interleukin-1 beta-dependent paracrine loop. *Am J Pathol.* 1998;152:523-532.
  134. Mitra D, Jaffe EA, Weksler B, et al. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. *Blood.* 1997;89:1224-1234.
  135. Tsuji S, Kaji K, Nagasawa S. Activation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cells. *J Biochem (Tokyo).* 1994;116:794-800.
  136. Bombeli T, Schwartz BR, Harlan JM. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. *Blood.* 1999;93:3831-3838.
  137. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. *J Exp Med.* 1997;186:1831-1841.
  138. Fujita M, Kuwano K, Kunitake R, et al. Endothelial cell apoptosis in lipopolysaccharide-induced lung injury in mice. *Int Arch Allergy Immunol.* 1998;117:202-208.
  139. Kawasaki M, Kuwano K, Hagimoto N, et al. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor. *Am J Pathol.* 2000;157:597-603.
  140. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. *Am J Respir Crit Care Med.* 2001;163:316-321.
  141. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. *J Immunol.* 2001;167:2887-2894.
  142. Bochkov VN, Kadl A, Huber J, et al. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. *Nature.* 2002;419:77-81.
  143. Cohen J, Guyatt G, Bernard GR, et al. New strategies for clinical trials in patients with sepsis and septic shock. *Crit Care Med.* 2001;29:880-886.
  144. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. *Am J Respir Crit Care Med.* 2002;166:1197-1205.
  145. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. *JAMA.* 2001;286:1869-1878.
  146. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. *Crit Care Med.* 1997;25:1095-1100.
  147. ARDSNET. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N Engl J Med.* 2000;342:1301-1308.
  148. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA.* 2002;288:862-871.
  149. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. *N Engl J Med.* 2001;345:1359-1367.
  150. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med.* 2001;345:1368-1377.
  151. Natanson C, Esposito CJ, Banks SM. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. *Crit Care Med.* 1998;26:1927-1931.
  152. Marshall JC. Clinical trials of mediator-directed therapy in sepsis: what have we learned? *Intensive Care Med.* 2000;26:S75-S83.
  153. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. *Crit Care Med.* 2002;30:S214-S219.
  154. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. *Proc Natl Acad Sci U S A.* 1995;92:7450-7454.
  155. Frenette PS, Moyna C, Hartwell DW, et al. Platelet-endothelial interactions in inflamed mesenteric venules. *Blood.* 1998;91:1318-1324.
  156. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIb/IIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1),  $\alpha$ v $\beta$ 3 integrin, and GPIIb/IIIa. *J Exp Med.* 1998;187:329-339.
  157. Coalson JJ, Benjamin B, Archer LT, et al. Prolonged shock in the baboon subjected to infusion of E coli endotoxin. *Circ Shock.* 1978;5:423-437.
  158. Taylor FB Jr, Chang AC, Peer GT, et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by *Escherichia coli* without preventing shock or organ damage. *Blood.* 1991;78:364-368.
  159. Emerson TE Jr, Fournel MA, Redens TB, Taylor FB Jr. Efficacy of antithrombin III supplementation in animal models of fulminant *Escherichia coli* endotoxemia or bacteremia. *Am J Med.* 1989;87:27S-33S.
  160. Taylor FB Jr, Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of *Escherichia coli* infusion in the baboon. *J Clin Invest.* 1987;79:918-925.
  161. Creasey AA, Chang AC, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from *Escherichia coli* septic shock. *J Clin Invest.* 1993;91:2850-2856.
  162. Welty-Wolf KE, Carraway MS, Miller DL, et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. *Am J Respir Crit Care Med.* 2001;164:1988-1996.
  163. Oelschlager C, Romisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor  $\kappa$ B activation in human monocytes and vascular endothelial cells. *Blood.* 2002;99:4015-4020.
  164. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. *J Biol Chem.* 2001;276:11199-11203.
  165. Souter PJ, Thomas S, Hubbard AR, et al. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. *Crit Care Med.* 2001;29:134-139.
  166. Crowther MA, Marshall JC. Continuing challenges of sepsis research. *JAMA.* 2001;286:1894-1896.
  167. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. *Crit Care Med.* 2002;30:S325-S331.
  168. Dimmeler S, Haendeler J, Rippmann V, Nehls M, Zeiher AM. Shear stress inhibits apoptosis of human endothelial cells. *FEBS Lett.* 1996;399:71-74.
  169. Baumgartner-Parzer SM, Wagner L, Pettermann M, et al. High-glucose-triggered apoptosis in cultured endothelial cells. *Diabetes.* 1995;44:1323-1327.
  170. Du XL, Sui GZ, Stockklauser-Farber K, et al. Introduction of apoptosis by high proinsulin and glucose in cultured human umbilical vein endothelial cells is mediated by reactive oxygen species. *Diabetologia.* 1998;41:249-256.
  171. Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. *Arterioscler Thromb Vasc Biol.* 2000;20:402-409.
  172. Stempien-Otero A, Karsan A, Cornejo CJ, et al. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. *J Biol Chem.* 1999;274:8039-8045.
  173. Matsushita H, Morishita R, Nata T, et al. Hypoxia-induced endothelial apoptosis through nuclear factor- $\kappa$ B (NF- $\kappa$ B)-mediated bcl-2 suppression: in vivo evidence of the importance of NF- $\kappa$ B in endothelial cell regulation. *Circ Res.* 2000;86:974-981.
  174. Stefanec T. The effects of statins on mortality rates among bacteremic patients [letter]. *Clin Infect Dis.* 2002;34:1158.
  175. Gratton JP, Morales-Ruiz M, Kureishi Y, et al. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. *J Biol Chem.* 2001;276:30359-30365.
  176. Denk A, Goebeler M, Schmid S, et al. Activation of NF- $\kappa$ B via the I $\kappa$ B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. *J Biol Chem.* 2001;276:28451-28458.
  177. Bohrer H, Qiu F, Zimmermann T, et al. Role of NF $\kappa$ B in the mortality of sepsis. *J Clin Invest.* 1997;100:972-985.
  178. Oitzinger W, Hofer-Warbinek R, Schmid JA, et al. Adenovirus-mediated expression of a mutant I $\kappa$ B kinase 2 inhibits the response of endothelial cells to inflammatory stimuli. *Blood.* 2001;97:1611-1617.
  179. Bohuslav J, Kravchenko VV, Parry GC, et al. Regulation of an essential innate immune response by the p50 subunit of NF- $\kappa$ B. *J Clin Invest.* 1998;102:1645-1652.
  180. Rudders S, Gaspar J, Madore R, et al. ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF- $\kappa$ B to regulate the inducible nitric-oxide synthase gene. *J Biol Chem.* 2001;276:3302-3309.
  181. Martin T, Cardarelli PM, Parry GC, Felts KA, Cobb RR. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF- $\kappa$ B and AP-1. *Eur J Immunol.* 1997;27:1091-1097.
  182. Ahmad M, Theofanis P, Medford RM. Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor- $\alpha$ . *J Biol Chem.* 1998;273:4616-4621.
  183. Hipp MS, Urbich C, Mayer P, et al. Proteasome inhibition leads to NF- $\kappa$ B-independent IL-8



- transactivation in human endothelial cells through induction of AP-1. *Eur J Immunol.* 2002;32:2208-2217.
184. Simoncini T, Maffei S, Basta G, et al. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. *Circ Res.* 2000;87:19-25.
  185. Umetani M, Matakai C, Minegishi N, et al. Function of GATA transcription factors in induction of endothelial vascular cell adhesion molecule-1 by tumor necrosis factor- $\alpha$ . *Arterioscler Thromb Vasc Biol.* 2001;21:917-922.
  186. Yan SF, Fujita T, Lu J, et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. *Nat Med.* 2000;6:1355-1361.
  187. Ye X, Liu SF. Lipopolysaccharide regulates constitutive and inducible transcription factor activities differentially in vivo in the rat. *Biochem Biophys Res Commun.* 2001;288:927-932.
  188. Liu SF, Ye X, Malik AB. Inhibition of NF- $\kappa$ B activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. *Circulation.* 1999;100:1330-1337.
  189. Gao Y, Lecker S, Post MJ, et al. Inhibition of ubiquitin-proteasome pathway-mediated I  $\kappa$ B  $\alpha$  degradation by a naturally occurring antibacterial peptide. *J Clin Invest.* 2000;106:439-448.
  190. De Bosscher K, Vanden Berghe W, Vermeulen L, et al. Glucocorticoids repress NF- $\kappa$ B-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. *Proc Natl Acad Sci U S A.* 2000;97:3919-3924.
  191. Bach FH, Hancock WW, Ferran C. Protective genes expressed in endothelial cells: a regulatory response to injury. *Immunol Today.* 1997;18:483-486.
  192. Zen K, Karsan A, Stempien-Otero A, et al. NF- $\kappa$ B activation is required for human endothelial survival during exposure to tumor necrosis factor- $\alpha$  but not to interleukin-1 $\beta$  or lipopolysaccharide. *J Biol Chem.* 1999;274:28808-28815.
  193. Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. *Mol Med Today.* 1999;5:439-447.
  194. Marin V, Farnarier C, Gres S, et al. The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. *Blood.* 2001;98:667-673.
  195. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF- $\alpha$  biosynthesis. *Nat Cell Biol.* 1999;1:94-97.
  196. Badger AM, Bradbeer JN, Votta B, et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. *J Pharmacol Exp Ther.* 1996;279:1453-1461.
  197. van den Blink B, Juffermans NP, ten Hove T, et al. p38 mitogen-activated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. *J Immunol.* 2001;166:582-587.
  198. Branger J, van den Blink B, Weijer S, et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. *J Immunol.* 2002;168:4070-4077.
  199. Rahman A, Anwar KN, Malik AB. Protein kinase C- $\zeta$  mediates TNF- $\alpha$ -induced ICAM-1 gene transcription in endothelial cells. *Am J Physiol Cell Physiol.* 2000;279:C906-C914.
  200. Minami T, Abid MR, Zhang J, et al. Thrombin stimulation of vascular adhesion molecule-1 in endothelial cells is mediated by protein kinase C (PKC)- $\delta$ -NF- $\kappa$ B and PKC- $\zeta$ -GATA signaling pathways. *J Biol Chem.* 2003;278:6976-6984.
  201. Frey RS, Rahman A, Kefer JC, Minshall RD, Malik AB. PKC $\zeta$  regulates TNF- $\alpha$ -induced activation of NADPH oxidase in endothelial cells. *Circ Res.* 2002;90:1012-1019.
  202. Leitges M, Sanz L, Martin P, et al. Targeted disruption of the zetaPKC gene results in the impairment of the NF- $\kappa$ B pathway. *Mol Cell.* 2001;8:771-780.
  203. Scott JA, Mehta S, Duggan M, Bihari A, McCormack DG. Functional inhibition of constitutive nitric oxide synthase in a rat model of sepsis. *Am J Respir Crit Care Med.* 2002;165:1426-1432.
  204. Liu SF, Adcock IM, Old RW, Barnes PJ, Evans TW. Differential regulation of the constitutive and inducible nitric oxide synthase mRNA by lipopolysaccharide treatment in vivo in the rat. *Crit Care Med.* 1996;24:1219-1225.
  205. Ermert M, Ruppert C, Gunther A, et al. Cell-specific nitric oxide synthase-isoenzyme expression and regulation in response to endotoxin in intact rat lungs. *Lab Invest.* 2002;82:425-441.
  206. Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. *Proc Natl Acad Sci U S A.* 1995;92:10688-10692.
  207. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. *Proc Natl Acad Sci U S A.* 1996;93:13176-13181.
  208. Yamashita T, Kawashima S, Ohashi Y, et al. Resistance to endotoxin shock in transgenic mice overexpressing endothelial nitric oxide synthase. *Circulation.* 2000;101:931-937.
  209. Avontuur JA, Boomsma F, van den Meiracker AH, de Jong FH, Bruining HA. Endothelin-1 and blood pressure after inhibition of nitric oxide synthesis in human septic shock. *Circulation.* 1999;99:271-275.
  210. Szabo C, Southan GJ, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. *Proc Natl Acad Sci U S A.* 1994;91:12472-12476.
  211. Okamoto I, Abe M, Shibata K, et al. Evaluating the role of inducible nitric oxide synthase using a novel and selective inducible nitric oxide synthase inhibitor in septic lung injury produced by cecal ligation and puncture. *Am J Respir Crit Care Med.* 2000;162:716-722.
  212. Cobb JP, Natanson C, Hoffman WD, et al. N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. *J Exp Med.* 1992;176:1175-1182.
  213. Wiel E, Pu Q, Corseaux D, et al. Effect of L-arginine on endothelial injury and hemostasis in rabbit endotoxin shock. *J Appl Physiol.* 2000;89:1811-1818.
  214. Cerwinka WH, Cooper D, Kriegelstein CF, Feelisch M, Granger DN. Nitric oxide modulates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules. *Am J Physiol Heart Circ Physiol.* 2002;282:H1111-H1117.
  215. Cohen J. Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. *Br Med Bull.* 1999;55:212-225.
  216. Dinarello CA, Abraham E. Does blocking cytokines in sepsis work? *Am J Respir Crit Care Med.* 2002;166:1156-1157.
  217. Marshall JC. Complexity, chaos, and incomprehensibility: parsing the biology of critical illness. *Crit Care Med.* 2000;28:2646-2648.
  218. Seely AJ, Christou NV. Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. *Crit Care Med.* 2000;28:2193-2200.
  219. Grinnell BW, Joyce D. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. *Crit Care Med.* 2001;29:S53-S60.
  220. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. *J Exp Med.* 2002;196:561-564.
  221. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest.* 1999;115:462-474.
  222. Opal SM, Yu RL Jr. Antidotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions. *Drugs.* 1998;55:497-508.
  223. Lynn WA. Anti-endotoxin therapeutic options for the treatment of sepsis. *J Antimicrob Chemother.* 1998;41(suppl A):71-80.
  224. Verbon A, Dekkers PE, ten Hove T, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. *J Immunol.* 2001;166:3599-3605.
  225. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. *Lancet.* 1998;351:929-933.
  226. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor- $\alpha$  in patients with sepsis. International Sepsis Trial Study Group. *Crit Care Med.* 1996;24:1431-1440.
  227. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. *Crit Care Med.* 2002;30:S294-S301.
  228. Fink MP. Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis. *J Antimicrob Chemother.* 1998;41(suppl A):81-94.
  229. Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. *JAMA.* 1997;277:482-487.
  230. Jansen PM, Pixley RA, Brouwer M, et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. *Blood.* 1996;87:2337-2344.
  231. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. *N Engl J Med.* 1997;336:912-918.
  232. Fink MP. Prostaglandins and sepsis: still a fascinating topic despite almost 40 years of research. *Am J Physiol Lung Cell Mol Physiol.* 2001;281:L534-L536.
  233. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. *Am J Respir Crit Care Med.* 2001;164:1768-1773.
  234. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. *Science.* 1999;285:248-251.
  235. Fiuzza C, Bustin M, Talwar S, et al. Inflammatory promoting activity of HMGB1 on human microvascular endothelial cells. *Blood.* Prepublished on November 27, 2002, as DOI 10.1182/blood-2002-05-1300.
  236. Laudes IJ, Chu JC, Sikranth S, et al. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. *Am J Pathol.* 2002;160:1867-1875.
  237. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. *Nat Med.* 1999;5:788-792.
  238. Basu S, Dunn AR, Marino MW, et al. Increased

- tolerance to endotoxin by granulocyte-macrophage colony-stimulating factor-deficient mice. *J Immunol.* 1997;159:1412-1417.
239. Hamilton JA. GM-CSF in inflammation and autoimmunity. *Trends Immunol.* 2002;23:403-408.
240. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. *Microbes Infect.* 2002;4:449-460.
241. Baugh JA, Bucala R. Macrophage migration inhibitory factor. *Crit Care Med.* 2002;30:S27-S35.
242. Selzman CH, Shames BD, Miller SA, et al. Therapeutic implications of interleukin-10 in surgical disease. *Shock.* 1998;10:309-318.
243. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. *J Exp Med.* 1993;177:1205-1208.
244. van der Poll T, Jansen PM, Montegut WJ, et al. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. *J Immunol.* 1997;158:1971-1975.
245. Fisher CJ Jr, Opal SM, Lowry SF, et al. Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. *Circ Shock.* 1994;44:1-8.
246. Dhainaut JF, Tenailon A, Le Tulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. *Crit Care Med.* 1994;22:1720-1728.
247. Dhainaut JF, Tenailon A, Hemmer M, et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. *Crit Care Med.* 1998;26:1963-1971.
248. Huber-Lang MS, Riedeman NC, Sarma JV, et al. Protection of innate immunity by C5aR antagonist in septic mice. *Faseb J.* 2002;16:1567-1574.
249. Lindner JR, Kahn ML, Coughlin SR, et al. Delayed onset of inflammation in protease-activated receptor-2-deficient mice. *J Immunol.* 2000;165:6504-6510.
250. Vogel SM, Gao X, Mehta D, et al. Abrogation of thrombin-induced increase in pulmonary microvascular permeability in PAR-1 knockout mice. *Physiol Genomics.* 2000;4:137-145.
251. Giebler R, Schmidt U, Koch S, Peters J, Scherer R. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to *Escherichia coli* endotoxin. *Crit Care Med.* 1999;27:597-604.
252. Caliezi C, Zeerleder S, Redondo M, et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. *Crit Care Med.* 2002;30:1722-1728.
253. Armour J, Tyni K, Lidington D, Wilson JX. Ascorbate prevents microvascular dysfunction in the skeletal muscle of the septic rat. *J Appl Physiol.* 2001;90:795-803.
254. Heller AR, Groth G, Heller SC, et al. N-acetylcysteine reduces respiratory burst but augments neutrophil phagocytosis in intensive care unit patients. *Crit Care Med.* 2001;29:272-276.
255. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. *Crit Care Med.* 1995;23:1430-1439.
256. Bradley C. Steroids in sepsis—more effective than activated protein C? *Intensive Crit Care Nurs.* 2001;17:242-244.
257. Carlet J. From mega to more reasonable doses of corticosteroids: a decade to recreate hope. *Crit Care Med.* 1999;27:672-674.
258. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. *Crit Care Med.* 2001;29:2081-2089.
259. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. *Intensive Care Med.* 1998;24:663-672.
260. Pu Q, Wiel E, Corseaux D, et al. Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in *Escherichia coli* endotoxin-induced shock. *Crit Care Med.* 2001;29:1181-1188.
261. Parker RI. IIb/IIIa or not IIb/IIIa, that is adhesion. *Crit Care Med.* 2001;29:1286-1287.
262. Taylor FB, Collier BS, Chang AC, et al. 7E3 F(ab')<sub>2</sub>, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of *Escherichia coli*. *Blood.* 1997;89:4078-4084.
263. Ferri LE, Swartz D, Christou NV. Soluble L-selectin at levels present in septic patients diminishes leukocyte-endothelial cell interactions in mice in vivo: a mechanism for decreased leukocyte delivery to remote sites in sepsis. *Crit Care Med.* 2001;29:117-122.
264. Taylor FB Jr, Chang A, Ruf W, et al. Lethal *E coli* septic shock is prevented by blocking tissue factor with monoclonal antibody. *Circ Shock.* 1991;33:127-134.
265. Biemond BJ, Levi M, ten Cate H, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. *Thromb Haemost.* 1995;73:223-230.
266. Zenz W, Bodo Z, Zobel G, Fanconi S, Rettenbacher A. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. *Crit Care Med.* 1998;26:969-971; discussion 972-963.
267. Umetani M, Nakao H, Doi T, et al. A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA. *Biochem Biophys Res Commun.* 2000;272:370-374.
268. Frank JA, Gutierrez JA, Jones KD, et al. Low tidal volume reduces epithelial and endothelial injury in acid-injured rat lungs. *Am J Respir Crit Care Med.* 2002;165:242-249.
269. Hasday JD, Bannerman D, Sakarya S, et al. Exposure to febrile temperature modifies endothelial cell response to tumor necrosis factor- $\alpha$ . *J Appl Physiol.* 2001;90:90-98.
270. Chettab K, Zibara K, Belaiba SR, McGregor JL. Acute hyperglycaemia induces changes in the transcription levels of 4 major genes in human endothelial cells: macroarrays-based expression analysis. *Thromb Haemost.* 2002;87:141-148.
271. Furuno T, Mitsuyama T, Hidaka K, Tanaka T, Hara N. The role of neutrophil elastase in human pulmonary artery endothelial cell injury. *Int Arch Allergy Immunol.* 1997;112:262-269.
272. MacGregor IR, Perrie AM, Donnelly SC, Haslett C. Modulation of human endothelial thrombomodulin by neutrophils and their release products. *Am J Respir Crit Care Med.* 1997;155:47-52.
273. Szabo C, Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL. Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. *J Clin Invest.* 1997;100:723-735.
274. Hassa PO, Hottiger MO. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF- $\kappa$ B in inflammatory disorders. *Cell Mol Life Sci.* 2002;59:1534-1553.
275. Oliver FJ, Menissier-de Murcia J, Nacci C, et al. Resistance to endotoxic shock as a consequence of defective NF- $\kappa$ B activation in poly (ADP-ribose) polymerase-1 deficient mice. *Embo J.* 1999;18:4446-4454.
276. Rahman A, Anwar KN, Uddin S, et al. Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. *Mol Cell Biol.* 2001;21:5554-5565.
277. Michiels C, Arnould T, Remacle J. Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. *Biochim Biophys Acta.* 2000;1497:1-10.
278. Fallor DV. Endothelial cell responses to hypoxic stress. *Clin Exp Pharmacol Physiol.* 1999;26:74-84.
279. Pinsky DJ, Liao H, Lawson CA, et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. *J Clin Invest.* 1998;102:919-928.
280. Pinsky DJ, Yan SF, Lawson C, et al. Hypoxia and modification of the endothelium: implications for regulation of vascular homeostatic properties. *Semin Cell Biol.* 1995;6:283-294.
281. Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. *Circulation.* 1996;94:1682-1689.
282. Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. *Arterioscler Thromb Vasc Biol.* 1998;18:677-685.
283. Surapitsitach J, Hoefen RJ, Pi X, et al. Fluid shear stress inhibits TNF- $\alpha$  activation of JNK but not ERK1/2 or p38 in human umbilical vein endothelial cells: inhibitory crosstalk among MAPK family members. *Proc Natl Acad Sci U S A.* 2001;98:6476-6481.
284. Hojo Y, Saito Y, Tanimoto T, et al. Fluid shear stress attenuates hydrogen peroxide-induced c-Jun NH2-terminal kinase activation via a glutathione reductase-mediated mechanism. *Circ Res.* 2002;91:712-718.
285. Conway EM, Van de Wouwer M, Pollefeys S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor  $\kappa$ B and mitogen-activated protein kinase pathways. *J Exp Med.* 2002;196:565-577.
286. Karpaliotis D, Kosmidou I, Ingenito EP, et al. Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. *Am J Physiol Lung Cell Mol Physiol.* 2002;283:L585-L595.
287. Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. *J Clin Invest.* 2002;109:1007-1009.
288. Colman RW. The contact system: a proinflammatory pathway with antithrombotic activity. *Nat Med.* 1998;4:277-278.
289. Pixley RA, De La Cadena R, Page JD, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. *J Clin Invest.* 1993;91:61-68.
290. Chiron announces results of phase III study of Tifacogin in severe sepsis [press release]. Emeryville, CA: Chiron. November 21, 2001.
291. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. *Science.* 2002;296:1880-1882.
292. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. *Nat Med.* 2003;9:338-342.